• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED for canine atopic dermatitis now available

September 7, 2021
dvm360 Staff
dvm360, dvm360 October 2021, Volume 52, Issue 10

CYCLAVANCE™ oral solution marks the first FDA-approved liquid cyclosporine for dogs in the United States.

Virbac Corporation has released CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED, an oral solution for the management of canine atopic dermatitis. Though veterinarians in the United States are familiar with cyclosporine in capsule form, CYCLAVANCE™ oral solution is the first FDA-approved liquid cyclosporine for dogs available in the country.

"Atopic dermatitis in dogs is a common chronic relapsing skin disease characterized by itchy and inflamed skin. The condition can cause discomfort and pain in dogs and often requires lifelong management," said Cristiano von Simson, DVM, MBA, marketing and veterinary services director at Virbac, in a company release.1

"Recommending a product that is easy for the client to administer correctly can significantly improve the long-term satisfaction with the treatment," he added.

Treatment guidelines from the International Committee on Allergic Diseases of Animals (ICADA) emphasize using a multimodal approach for atopic dermatitis treatment while also including a plan for broad inflammation management.2,3 Along with removing or avoiding known flare factors, the ICADA Guidelines recommend cyclosporine as part of a multi-faceted approach to controlling acute flare-ups.2,3

Additionally, CYCLAVANCE™ oral solution has demonstrated higher acceptance rate by dogs when compared to cyclosporine capsules.3,4 CYCLAVANCE™ oral solution as a liquid formulation has been shown to have a greater than 98% acceptance rate by dogs when administered either directly in the mouth or when combined with a small amount of food.4 According to the release, the delivery system also enables precise dosing at 5 mg/kg for all dogs, with greater accuracy than when dosing with capsules.

Advertisement

“The management of atopic dermatitis is complex and our thinking about it has evolved in recent years,” says von Simson. "The ICADA Guidelines acknowledge the importance of cyclosporine as part of a multimodal treatment approach—an approach that includes a plan for managing both inflammation and pruritus.”

CYCLAVANCE™ is for use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose. The product should be used with caution in cases involving diabetes mellitus (it can cause elevated levels of serum glucose); in dogs with renal insufficiency (the effect of cyclosporine use on dogs with compromised renal function has not been studied); in simultaneous administration with drugs that suppress the P-450 enzyme system (that may lead to increased plasma levels of cyclosporine).

Killed vaccines are recommended for dogs receiving CYCLAVANCE™ because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. To receive prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

To learn more about CYCLAVANCE™, go here.

References

  1. Virbac announces availability of CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED for atopic dermatitis in dogs. News release. July 23, 2021; Circa Healthcare. Accessed September 7, 2021. https://www.einnews.com/pr_news/547029441/virbac-announces-availability-of-cyclavance-tm-cyclosporine-oral-solution-usp-modified-for-atopic-dermatitis-in-dogs
  2. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21:233-248.
  3. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210:1–15.
  4. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studies. Ir Vet J. 2015;68:3.
download issueDownload Issue: dvm360 October 2021

Related Content:

ProductsDermatologyTechniciansRolesAssociatesdvm360 October 2021
Expert shares pet care tips for springtime
Expert shares pet care tips for springtime
Veterinary tech students awarded national scholarship
Veterinary tech students awarded national scholarship
Paw Prosper acquires brands and becomes one-stop destination for pet aging
Paw Prosper acquires brands and becomes one-stop destination for pet aging

Advertisement

Latest News

Xylazine moves from the stables to the streets

DEA reports widespread threat of fentanyl mixed with xylazine

3 Must-reads for National Poison Prevention Week

UC Davis study on eye diseases in kittens

View More Latest News
Advertisement